Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, announced that several regulatory agencies around the world have added licenses of the best-in-class GastroPlus™ and ADMET Predictor™ software within the past three months.

The Company has received orders from:

  • The National Institutes for Food and Drug Control in China
  • The Pharmaceutical and Medical Devices Agency in Japan
  • The U.S. Food and Drug Administration
  • The Environmental Protection Agency

John DiBella, vice president for marketing and sales for Simulations Plus, said: “We are very pleased that the use of our modeling and simulation technology continues to expand throughout various divisions and departments at regulatory agencies around the globe. We plan to host training workshops at several agencies over the coming months to ensure that researchers are educated on the latest developments and to maintain an open dialogue to receive feedback and identify potential new applications. There has been a significant push from regulatory groups to industry on the adoption of modeling and simulation to more effectively design and develop new drugs and products, and we look forward to supporting these efforts.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus recently acquired Cognigen Corporation adding top quality modeling and simulations using clinical trial data to our offerings. The acquisition more than doubled our staff and added significantly to revenues. The Company is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” Cognigen Corp is located in Buffalo, New York. For more information, visit our Web site at

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.


Simulations Plus Investor Relations
Ms. Renee Bouche, 661-723-7723
Hayden IR
Mr. Cameron Donahue, 651-653-1854